Natco Pharma Peer Comparison

NSE: NATCOPHARM | BSE: 524816

₹805.05

₹-1.95 (-0.24%)

As on 08-Nov-2026IST

Market cap

₹15,804 Cr

Revenue (TTM)

₹3,485 Cr

P/E Ratio

13.8

P/B Ratio

1.5

Div. Yield

0.6 %

Edit

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	15,804	32,758	32,619	32,170	28,473
Revenue (₹ Cr)	3,485	9,779	3,751	1,593	2,100
Net Profit (₹ Cr)	1,013.80	-270.51	405.00	438.64	324.79
Net Margin (%)	26.82	-2.71	10.48	27.16	15.36
RoE (%)	12.81	-2.55	7.91	25.02	24.02
Price to Earnings	13.81	--	79.56	73.25	87.65
Price-To-Book	1.49	4.02	6.32	17.32	20.10

Income Statement (₹ Cr)

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Operating Revenue	3,484.60	9,778.62	3,751.00	1,592.52	2,100.17
Total Income	3,779.70	9,993.26	3,863.00	1,615.23	2,114.53
Total Expenditure	2,432.60	8,578.44	2,984.00	969.32	1,600.14
EBITDA	1,052.00	1,200.18	767.00	623.20	500.03
Depreciation	196.10	887.82	228.00	41.96	57.00
EBIT	855.90	312.36	539.00	581.24	443.03
Interest	46.50	347.94	218.00	4.21	40.83
Other Income	295.10	214.64	112.00	22.71	14.37
Exceptional Items	0.00	-216.88	12.00	0.00	0.00
Profit before Tax	1,104.50	-37.82	445.00	599.74	416.57
Provision for Tax	90.70	232.69	40.00	161.10	91.78
Profit after Tax	1,013.80	-270.51	405.00	438.64	324.79

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	9,221.10	8,142.24	5,158.00	1,857.45	1,416.33
Minority Interest	-0.40	0.55	5.00	0.51	0.05
Non-Current Liabilities	171.70	5,213.99	1,617.00	47.15	376.76
Current Liabilities	1,680.90	5,158.51	1,785.00	253.37	952.98
Total Liabilities	11,073.50	17,723.32	8,578.00	1,983.96	2,326.71

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Non-Current Assets	5,877.90	10,687.30	5,527.00	1,132.12	798.30
Current Assets	5,052.30	7,253.65	2,764.00	1,012.00	1,747.21
Total Assets	11,073.50	17,723.32	8,578.00	1,983.96	2,326.71
Total Debt*	706.40	5,495.48	2,125.00	26.49	259.37
Net Current Assets	3,371.40	2,095.14	979.00	758.64	794.23
Contingent Liabilities	3.00	95.72	768.26	17.25	19.09

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	1,768.30	1,652.60	390.00	292.17	205.05
Cash Flow from Investing Activities	-2,081.70	-826.03	-241.00	-265.94	-409.72
Cash from Financing Activities	297.50	-38.98	-54.00	4.10	283.07
Net Cash Inflow / Outflow	-15.90	787.59	95.00	30.33	78.39

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
ROCE (%)	17.16	1.24	6.79	32.42	29.22
ROE (%)	12.81	-2.55	7.91	25.02	24.02
ROA (%)	10.29	-1.56	4.65	22.40	14.30
EBIT Margin (%)	24.56	3.19	14.37	36.50	21.09
Net Margin (%)	26.82	-2.71	10.48	27.16	15.36
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-20.73	9.43	25.70	45.18	46.25
EBIT Growth (%)	-50.05	-3.72	139.56	115.51	60.95
Net Profit Growth (%)	-40.20	-199.34	894.12	95.80	89.41
EPS Growth (%)	-32.59	-410.28	599.72	63.29	76.32
Book Value Growth (%)	21.22	0.33	13.47	26.03	144.31

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Price / Earnings	12.61	-157.53	81.64	73.25	87.48
Price / Book Value	1.49	4.02	6.32	17.32	20.10
Dividend Yield (%)	0.61	0.00	0.00	0.06	0.09
EV/EBITDA	13.67	30.74	44.43	51.30	56.77
Market Cap (₹ Cr)	17,452.68	18,108.89	19,071.62	20,944.75	12,753.19

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.01	0.55	0.28	0.02	0.13
Short term debt to equity ratio	0.03	0.09	0.09	0.00	0.05
Current Ratio	3.01	1.41	1.55	3.99	1.83
Quick Ratio	2.47	0.77	1.00	2.89	1.00
Interest Coverage	24.75	0.89	3.04	143.52	11.20

	Natco Pharma	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	25.29	23.05	16.85	22.50	27.51
Asset Turnover	0.35	0.56	0.43	0.81	0.92
Receivable days	82.64	78.20	58.75	88.98	40.13
Inventory Days	65.03	93.30	75.82	56.04	60.29
Payable days	202.84	226.14	186.21	99.95	232.47
Cash Conversion Cycle	-55.16	-54.64	-51.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.